Guggenheim downgraded IGM Biosciences (IGMS) to Neutral from Buy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences downgraded to Sector Perform from Outperform at RBC Capital
- IGM Biosciences downgraded to Hold from Buy at Stifel
- IGM Biosciences downgraded to Underweight from Equal Weight at Morgan Stanley
- IGM Biosciences downgraded to Market Perform from Outperform at BMO Capital
- IGM Biosciences reducing workforce by 73%, evaluating strategic alternatives
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue